ArticleFrontiers in oncology2020
Case Report: Gastrointestinal PEComa With
Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 26 citations in OpenAlex.
- TFE3-rearranged PEComa with hepatic and pulmonary involvement: diagnostic challenges and resistance to mTOR-targeted therapy.Journal of cancer research and clinical oncology · 2026Article
- TFE3-Rearranged PEComa(-Like Neoplasm) of the Chest Wall Diagnosed by Fine-Needle Aspiration: A Case Report.Diagnostic cytopathology · 2026Article
- Clinicopathological and molecular features of gynecologic perivascular epithelioid cell tumors: a single-center study.Frontiers in oncology · 2026Article
- Genetic correlates of malignancy in TFE3-rearranged PEComa: a series of 14 cases.Histopathology · 2025Article
- TFE3-rearranged PEComa-like neoplasm of the kidney with carcinoma-like morphology and rapid progression: a case report.World journal of surgical oncology · 2025Article
- PEComa progressed by mTOR inhibitor therapy with anti-VEGFR TKI combined with PD-1 inhibitor: a case report.Frontiers in oncology · 2025Article
- Case Report: Malignant perivascular epithelioid cell tumor with aggressive mediastinal invasion and pulmonary metastasis.Frontiers in oncology · 2025Article
- A retrospective clinical analysis of 11 cases of PEComa from different sites.World journal of surgical oncology · 2024Article
- A Case Report of Malignant Perivascular Epithelioid Cell Tumors of the Uterus and Literature Review.International journal of women's health · 2024Article
- Case report: Malignant epithelioid angiosarcoma in a Chinese female patient.Frontiers in oncology · 2024Article
- Epithelioid Angiomyolipoma with Tumor Thrombus into Inferior Vena Cava Presurgically Treated with Combination Therapy of Pembrolizumab and Axitinib: A Case Report.Research and reports in urology · 2023Article
- Management Strategies for Adults with Locally Advanced, Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa): Challenges and Solutions.Cancer management and research · 2023Review
- Advancements in the diagnosis and treatment of renal epithelioid angiomyolipoma: A narrative review.The Kaohsiung journal of medical sciences · 2022Review
- Recent advances in targeted drug delivery systems for resistant colorectal cancer.Cancer cell international · 2022Review
- TFE3-associated perivascular epithelioid cell tumor with complete response to mTOR inhibitor therapy: report of first case and literature review.World journal of surgical oncology · 2022Review
- Case Report: Perivascular epithelioid tumors of the gastrointestinal tract.Frontiers in oncology · 2022Article
- A Rare Case of a Translocation-Associated Perivascular Epithelioid Cell Neoplasm (PEComa).Case reports in pediatrics · 2022Article
- Tuberous Sclerosis Complex With Multiple Organ Tumors: Case Report and Literature Review.Frontiers in oncology · 2022Review
- Case report: Kidney perivascular epithelioid cell tumor treated with anti-VEGFR tyrosine kinase inhibitor and MTOR inhibitor.Frontiers in oncology · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Perivascular epithelioid cell tumors (PEComas) are rare mesenchymal tumors. Unresectable malignant PEComas with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.